First-line treatment debate for an antibody–drug conjugate in advanced triple-negative breast cancer, previewing regulatory review and clinical-context reporting.
Key Takeaways
- China's NMPA CDE accepted a first-line indication application for sacituzumab tirumotecan in advanced TNBC
- Acceptance was based on positive Phase III OptiTROP-Breast03 results showing significant efficacy versus chemotherapy
- Application entered NMPA priority review and is the sixth indication submission for sac-TMT in China